Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, researchers are using the same tactics to advance prostate cancer treatment.
An individual-patient meta-analysis sheds light on the optimal duration of androgen deprivation therapy in men with prostate cancer on definitive radiotherapy.
Hosted on MSN
First-of-its-kind genomic test predicts benefit from hormone therapy added to radiation for recurrent prostate cancer
A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery—the ...
A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery - the ...
Advanced digital pathology and biopsy analysis are used to identify patients who benefit from intensified prostate cancer treatment. The STAMPEDE trial demonstrated that adding Zytiga to standard ...
Among prostate cancer patients with a luminal B subtype, the 5-year biochemical progression-free survival rate was 72% in the apalutamide group and 54% in the placebo group. Recurrent prostate cancer ...
News-Medical.Net on MSN
PSA-based tool improves decision making for prostate cancer screening and treatment
Prostate cancer is the second-leading cause of cancer death in American men. About 1 in 8 men will be diagnosed with prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results